For Immediate Release
Chicago, IL – August 9, 2022 – Stocks in this week’s article are Heska Corp. (
HSKA Quick Quote HSKA - Free Report) , Tandem Diabetes Care, Inc. ( TNDM Quick Quote TNDM - Free Report) , Credit Suisse Group ( CS Quick Quote CS - Free Report) , Zalando SE ( ZLNDY Quick Quote ZLNDY - Free Report) and Las Vegas Sands ( LVS Quick Quote LVS - Free Report) . 5 Toxic Stocks That May Prove Hazardous to Your Portfolio
There are always some stocks, which illusively scale lofty heights in a given time period. However, the good show doesn't last for these overblown toxic stocks as their current price is not justified by their fundamental strength.
Toxic companies are usually characterized by huge debt loads and are vulnerable to external shocks. Accurately identifying such bloated stocks and getting rid of them at the right time can protect your portfolio.
Overpricing of these toxic stocks can be attributed to either an irrational enthusiasm surrounding them or some serious fundamental drawbacks. If you own such bubble stocks for an inordinate period of time, you are bound to see a massive erosion of wealth.
However, if you can precisely spot such toxic stocks, you may gain by resorting to an investing strategy called short selling. This strategy allows one to sell a stock first and then buy it when the price falls.
While short selling excels in bear markets, it typically loses money in bull markets.
So, just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses or make profits by short selling them.
Heska Corp., Tandem Diabetes Care, Inc., Credit Suisse Group, Zalando SE and Las Vegas Sands are a few such toxic stocks. Here are five of the 20 stocks that made it through the screen:
Heska sells advanced veterinary diagnostic and specialty products, primarily focused on canine and feline healthcare markets. The company currently carries a Zacks Rank #5 (Strong Sell) and has a VGM Score of F. The Zacks Consensus Estimate for HSKA's 2022 bottom line implies a year-over-year decline of 10.6%. The consensus mark has moved south by 22 cents over the past seven days.
Headquartered in California,
Tandem Diabetes designs, develops and markets products for people with insulin-dependent diabetes. The company currently carries a Zacks Rank #5 and has a VGM Score of D. The Zacks Consensus Estimate for TNDM's 2022 bottom line implies a year-over-year plunge of 161.5%. The consensus mark has deteriorated from earnings of 35 cents a share to a loss of 16 cents over the past seven days.
Based in Switzerland,
Credit Suisse offers investment products, private banking and financial advisory services, as well as insurance and pension solutions. The company currently carries a Zacks Rank #5 and has a VGM Score of C. The Zacks Consensus Estimate for CS's 2022 bottom line implies a year-over-year slump of 666.7%. The consensus mark has deteriorated from earnings of 11 cents a share to a loss of 69 cents over the past 30 days.
Headquartered in Berlin,
Zalando is an online fashion retailer offering clothing, sports products, shoes, bags and other accessories for men, women and children. The company currently carries a Zacks Rank #4 (Sell) and has a VGM Score of F. The Zacks Consensus Estimate for ZLNDY's 2022 earnings implies a year-over-year decline of 73%. The consensus mark has moved south by 25 cents in the past 60 days. Las Vegas Sands is an international developer of multi-use integrated resorts, primarily operating in the United States and Asia. Based in Las Vegas, LVS carries a Zacks Rank #4 and has a VGM Score of F. The Zacks Consensus Estimate for Las Vegas' 2022 bottom line is pegged at a loss of $1.10 a share. The consensus mark of loss per share has widened from 89 cents to $1.10 in the past 30 days.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/1965159/5-toxic-stocks-that-may-prove-hazardous-for-your-portfolio Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year.
See these high-potential stocks free >>.
Follow us on Twitter:
Join us on Facebook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.